A detailed history of Beacon Investment Advisory Services, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Beacon Investment Advisory Services, Inc. holds 74,334 shares of ABBV stock, worth $13.4 Million. This represents 0.62% of its overall portfolio holdings.

Number of Shares
74,334
Previous 72,834 2.06%
Holding current value
$13.4 Million
Previous $12.5 Million 17.51%
% of portfolio
0.62%
Previous 0.54%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$163.84 - $199.33 $245,760 - $298,995
1,500 Added 2.06%
74,334 $14.7 Million
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $172,281 - $201,185
-1,113 Reduced 1.51%
72,834 $12.5 Million
Q1 2024

May 09, 2024

BUY
$159.82 - $182.1 $1.98 Million - $2.26 Million
12,419 Added 20.18%
73,947 $13.5 Million
Q4 2023

Feb 12, 2024

BUY
$137.6 - $154.97 $1.67 Million - $1.88 Million
12,150 Added 24.61%
61,528 $9.53 Million
Q3 2023

Oct 31, 2023

SELL
$133.59 - $154.65 $124,105 - $143,669
-929 Reduced 1.85%
49,378 $7.36 Million
Q2 2023

Jul 21, 2023

SELL
$132.51 - $164.9 $470,410 - $585,395
-3,550 Reduced 6.59%
50,307 $6.78 Million
Q1 2023

May 04, 2023

SELL
$144.61 - $166.54 $30,657 - $35,306
-212 Reduced 0.39%
53,857 $8.58 Million
Q4 2022

Jan 13, 2023

SELL
$138.31 - $165.87 $335,401 - $402,234
-2,425 Reduced 4.29%
54,069 $0
Q3 2022

Oct 20, 2022

SELL
$134.21 - $153.93 $200,107 - $229,509
-1,491 Reduced 2.57%
56,494 $7.58 Million
Q2 2022

Jul 21, 2022

SELL
$137.62 - $174.96 $238,357 - $303,030
-1,732 Reduced 2.9%
57,985 $8.88 Million
Q1 2022

May 12, 2022

SELL
$131.98 - $163.75 $372,051 - $461,611
-2,819 Reduced 4.51%
59,717 $9.68 Million
Q4 2021

Feb 04, 2022

SELL
$107.43 - $135.93 $240,428 - $304,211
-2,238 Reduced 3.46%
62,536 $8.47 Million
Q3 2021

Nov 09, 2021

SELL
$106.4 - $120.78 $601,160 - $682,407
-5,650 Reduced 8.02%
64,774 $6.99 Million
Q2 2021

Aug 02, 2021

BUY
$105.21 - $117.21 $15,991 - $17,815
152 Added 0.22%
70,424 $7.93 Million
Q1 2021

May 21, 2021

SELL
$102.3 - $112.62 $51,456 - $56,647
-503 Reduced 0.71%
70,272 $7.61 Million
Q4 2020

Feb 08, 2021

SELL
$80.49 - $108.67 $43,464 - $58,681
-540 Reduced 0.76%
70,775 $7.58 Million
Q3 2020

Oct 29, 2020

SELL
$85.91 - $100.83 $601 - $705
-7 Reduced 0.01%
71,315 $6.25 Million
Q2 2020

Jul 28, 2020

SELL
$73.37 - $98.18 $231,702 - $310,052
-3,158 Reduced 4.24%
71,322 $7 Million
Q1 2020

May 05, 2020

SELL
$64.5 - $97.79 $2.42 Million - $3.67 Million
-37,500 Reduced 33.49%
74,480 $5.68 Million
Q4 2019

Jan 31, 2020

BUY
$72.13 - $90.25 $7.56 Million - $9.46 Million
104,789 Added 1457.22%
111,980 $9.92 Million
Q3 2019

Oct 29, 2019

SELL
$62.98 - $75.72 $360,371 - $433,269
-5,722 Reduced 44.31%
7,191 $545,000
Q2 2019

Aug 07, 2019

SELL
$65.7 - $83.98 $8.24 Million - $10.5 Million
-125,404 Reduced 90.66%
12,913 $939,000
Q1 2019

May 15, 2019

SELL
$77.14 - $90.79 $712,156 - $838,173
-9,232 Reduced 6.26%
138,317 $11.1 Million
Q4 2018

Feb 08, 2019

BUY
$77.85 - $96.01 $1.14 Million - $1.41 Million
14,647 Added 11.02%
147,549 $13.6 Million
Q3 2018

Nov 09, 2018

SELL
$88.91 - $98.84 $428,012 - $475,815
-4,814 Reduced 3.5%
132,902 $12.6 Million
Q2 2018

Aug 09, 2018

SELL
$89.78 - $106.23 $200,209 - $236,892
-2,230 Reduced 1.59%
137,716 $12.8 Million
Q1 2018

Apr 26, 2018

BUY
$92.01 - $123.21 $287,163 - $384,538
3,121 Added 2.28%
139,946 $13.2 Million
Q4 2017

Feb 02, 2018

SELL
$89.56 - $98.21 $1.37 Million - $1.5 Million
-15,304 Reduced 10.06%
136,825 $13.2 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $10.6 Million - $13.6 Million
152,129
152,129 $13.5 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Beacon Investment Advisory Services, Inc. Portfolio

Follow Beacon Investment Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Beacon Investment Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Beacon Investment Advisory Services, Inc. with notifications on news.